Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?
ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.
ILMN - Illumina, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$156.27
DETAILS
HIGH:
$200.00
LOW:
$122.00
MEDIAN:
$155.00
CONSENSUS:
$156.27
DOWNSIDE:
19.03%
Stock News
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat
Illumina commands 90%+ market share in genomics sequencing, powering a $30B+ TAM growing at double digits with a robust razor-and-blades model. Post-GRAIL, management's renewed focus on core sequencing, cost control, and capital return is driving revenue recovery, margin expansion, and free cash flow. NovaSeq X placements and consumables pull-through are key near-term catalysts; 65%+ of consumables revenue is clinical, supporting high margins and recurring cash flows.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world.
Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue?
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Continue to Hold ILMN Stock in Your Portfolio?
Illumina builds on strong NovaSeq X demand and clinical sequencing momentum, but China weakness and cost pressures keep challenges in focus.
AZN vs. ILMN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why Illumina (ILMN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026.
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina (ILMN): Bullish Structure Builds After Breakout
Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights.
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
The cancer test maker could still have a bright future.
ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?
Illumina shares surge 98.7% in a year as NovaSeq X adoption accelerates, clinical sequencing demand grows, and the company tops Q1 2026 guidance.
Price Targets
Illumina price target raised to $200 from $180 at Guggenheim
$200.00
(was $176.55)
Guggenheim
Illumina resumed with a Market Perform at Bernstein
$185.00
(was $177.65)
Bernstein
Illumina price target raised to $180 from $170 at Guggenheim
$180.00
(was $162.96)
Guggenheim
Illumina resumed with an Outperform at RBC Capital
$170.00
(was $143.24)
RBC Capital
Illumina upgraded to Outperform from Neutral at Daiwa
$155.00
(was $145.00)
Illumina to Outperform
·
Daiwa
Illumina price target lowered to $140 from $150 at Canaccord
$140.00
(was $126.74)
Canaccord Genuity
Illumina price target raised to $122 from $110 at Barclays
$122.00
(was $126.74)
Barclays
Illumina price target lowered to $170 from $195 at Piper Sandler
$170.00
(was $119.72)
Piper Sandler
Illumina price target raised to $137 from $132 at Baird
$137.00
(was $120.22)
Catherine Ramsey Schulte
·
Robert W. Baird
Illumina price target raised to $135 from $120 at UBS
$135.00
(was $121.27)
UBS
Illumina price target lowered to $150 from $155 at Evercore ISI
$150.00
(was $121.13)
Evercore ISI
Illumina price target raised to $170 from $144 at Guggenheim
$170.00
(was $150.38)
Subbu Nambi
·
Guggenheim
Illumina price target raised to $150 from $130 at Canaccord
$150.00
(was $150.28)
Canaccord Genuity
Illumina price target raised to $155 from $135 at Stifel
$155.00
(was $141.65)
Daniel Arias
·
Stifel Nicolaus
Illumina price target raised to $155 from $142 at Evercore ISI
$155.00
(was $138.50)
Vijay Kumar
·
Evercore ISI
Illumina price target raised to $144 from $114 at Guggenheim
$144.00
(was $138.11)
Guggenheim
Illumina price target raised to $110 from $100 at Barclays
$110.00
(was $134.85)
Barclays
Illumina price target raised to $142 from $132 at Evercore ISI
$142.00
(was $121.59)
Vijay Kumar
·
Evercore ISI
Illumina price target raised to $109 from $105 at Baird
$109.00
(was $115.78)
Robert W. Baird
Illumina price target raised to $120 from $110 at UBS
$120.00
(was $115.78)
UBS